NZ600947A - Fused Aromatic Difluoromethanephosphonates as Protein Tyrosine Phosphatase 1B (PTP-1B) Inhibitors - Google Patents
Fused Aromatic Difluoromethanephosphonates as Protein Tyrosine Phosphatase 1B (PTP-1B) InhibitorsInfo
- Publication number
- NZ600947A NZ600947A NZ600947A NZ60094708A NZ600947A NZ 600947 A NZ600947 A NZ 600947A NZ 600947 A NZ600947 A NZ 600947A NZ 60094708 A NZ60094708 A NZ 60094708A NZ 600947 A NZ600947 A NZ 600947A
- Authority
- NZ
- New Zealand
- Prior art keywords
- ptp
- inhibitors
- protein tyrosine
- difluoromethanephosphonates
- tyrosine phosphatase
- Prior art date
Links
- -1 Aromatic Difluoromethanephosphonates Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 title 2
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 title 2
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 abstract 2
- 101710128896 Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- VCZSWBWTNMSIIT-UHFFFAOYSA-N diazanium;[(6-bromo-2-cyanoquinolin-7-yl)-difluoromethyl] phosphate Chemical compound [NH4+].[NH4+].N#CC1=CC=C2C=C(Br)C(C(F)(F)OP([O-])(=O)[O-])=CC2=N1 VCZSWBWTNMSIIT-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 abstract 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3834—Aromatic acids (P-C aromatic linkage)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89770007P | 2007-01-26 | 2007-01-26 | |
| PCT/CA2008/000172 WO2008089581A1 (en) | 2007-01-26 | 2008-01-24 | Fused aromatic ptp-1b inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ600947A true NZ600947A (en) | 2012-12-21 |
Family
ID=39644072
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ600947A NZ600947A (en) | 2007-01-26 | 2008-01-24 | Fused Aromatic Difluoromethanephosphonates as Protein Tyrosine Phosphatase 1B (PTP-1B) Inhibitors |
| NZ578296A NZ578296A (en) | 2007-01-26 | 2008-01-24 | Fused aromatic ptp-1b inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ578296A NZ578296A (en) | 2007-01-26 | 2008-01-24 | Fused aromatic ptp-1b inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8168815B2 (enExample) |
| EP (1) | EP2114971B1 (enExample) |
| JP (1) | JP5570223B2 (enExample) |
| KR (1) | KR101568799B1 (enExample) |
| CN (1) | CN102317296B (enExample) |
| AU (1) | AU2008209296B2 (enExample) |
| BR (1) | BRPI0806789B8 (enExample) |
| CA (1) | CA2675142C (enExample) |
| DK (1) | DK2114971T3 (enExample) |
| ES (1) | ES2547386T3 (enExample) |
| IL (1) | IL199742A (enExample) |
| MX (1) | MX2009007911A (enExample) |
| NZ (2) | NZ600947A (enExample) |
| RU (1) | RU2462469C2 (enExample) |
| WO (1) | WO2008089581A1 (enExample) |
| ZA (1) | ZA200904679B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008089581A1 (en) * | 2007-01-26 | 2008-07-31 | Merck Frosst Canada Ltd. | Fused aromatic ptp-1b inhibitors |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CA2870488A1 (en) * | 2012-04-16 | 2013-10-24 | Kaneq Pharma Inc. | Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors |
| WO2014141110A2 (en) * | 2013-03-14 | 2014-09-18 | Curadev Pharma Pvt. Ltd. | Aminonitriles as kynurenine pathway inhibitors |
| WO2015127548A1 (en) | 2014-02-28 | 2015-09-03 | The Royal Institution For The Advancement Of Learning / Mcgill University | Tc-ptp inhibitors as apc activators for immunotherapy |
| CN108159069A (zh) * | 2018-01-26 | 2018-06-15 | 广东省微生物研究所（广东省微生物分析检测中心） | 灰树花多糖f2在制备治疗高脂血症药物、预防或延缓动脉粥样硬化药物中的应用 |
| WO2023220833A1 (en) * | 2022-05-19 | 2023-11-23 | Kanyr Pharma Inc. | Combined inhibition of tyrosine phosphatases tcptp and ptp1b and pd-1 blockage immunotherapy in the treatment of cancer |
| WO2024123585A1 (en) * | 2022-12-05 | 2024-06-13 | Merck Sharp & Dohme Llc | Substituted quinazoline derivatives and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI83421C (fi) * | 1989-06-21 | 1991-07-10 | Huhtamaeki Oy | Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat. |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| US6174874B1 (en) * | 1998-09-21 | 2001-01-16 | Merck Frosst Canada & Co. | Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B) |
| JP2003518130A (ja) * | 1999-12-22 | 2003-06-03 | メルク フロスト カナダ アンド カンパニー | 蛋白チロシンホスファターゼ１ｂ（ｐｔｐ−１ｂ）阻害薬としてのホスホン酸誘導体 |
| CA2402414A1 (en) * | 2000-03-22 | 2001-09-27 | Christopher Bayly | Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| AU7705601A (en) | 2000-07-25 | 2002-02-05 | Merck & Co Inc | N-substituted indoles useful in the treatment of diabetes |
| CA2495943C (en) | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| UA84050C2 (en) * | 2004-01-30 | 2008-09-10 | Медивир Аб | Hcv ns-3-serine protease inhibitors |
| JP4922924B2 (ja) | 2004-04-13 | 2012-04-25 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃｅｔｐ阻害薬 |
| DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
| WO2006055525A2 (en) | 2004-11-15 | 2006-05-26 | Ceptyr, Inc. | Protein tyrosine phosphatase inhibitors and methods of use thereof |
| WO2008089581A1 (en) * | 2007-01-26 | 2008-07-31 | Merck Frosst Canada Ltd. | Fused aromatic ptp-1b inhibitors |
-
2008
- 2008-01-24 WO PCT/CA2008/000172 patent/WO2008089581A1/en not_active Ceased
- 2008-01-24 NZ NZ600947A patent/NZ600947A/xx not_active IP Right Cessation
- 2008-01-24 CA CA2675142A patent/CA2675142C/en not_active Expired - Fee Related
- 2008-01-24 ES ES08706319.4T patent/ES2547386T3/es active Active
- 2008-01-24 KR KR1020097017809A patent/KR101568799B1/ko not_active Expired - Fee Related
- 2008-01-24 MX MX2009007911A patent/MX2009007911A/es active IP Right Grant
- 2008-01-24 US US12/518,899 patent/US8168815B2/en active Active
- 2008-01-24 BR BRPI0806789A patent/BRPI0806789B8/pt not_active IP Right Cessation
- 2008-01-24 NZ NZ578296A patent/NZ578296A/en not_active IP Right Cessation
- 2008-01-24 EP EP08706319.4A patent/EP2114971B1/en not_active Not-in-force
- 2008-01-24 CN CN200880010110.9A patent/CN102317296B/zh not_active Expired - Fee Related
- 2008-01-24 JP JP2009546627A patent/JP5570223B2/ja not_active Expired - Fee Related
- 2008-01-24 DK DK08706319.4T patent/DK2114971T3/en active
- 2008-01-24 AU AU2008209296A patent/AU2008209296B2/en not_active Ceased
- 2008-01-24 RU RU2009132092/04A patent/RU2462469C2/ru not_active IP Right Cessation
-
2009
- 2009-07-03 ZA ZA200904679A patent/ZA200904679B/xx unknown
- 2009-07-07 IL IL199742A patent/IL199742A/en active IP Right Grant
-
2012
- 2012-03-13 US US13/418,956 patent/US8481742B2/en not_active Expired - Fee Related
-
2013
- 2013-05-21 US US13/898,947 patent/US8927526B2/en active Active
-
2014
- 2014-10-28 US US14/525,396 patent/US9334295B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ600947A (en) | Fused Aromatic Difluoromethanephosphonates as Protein Tyrosine Phosphatase 1B (PTP-1B) Inhibitors | |
| MX2010003927A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b. | |
| NZ613807A (en) | Phosphorus-containing group-substituted quinoline, its preparation process, medical composition containing the compound and application | |
| MY142029A (en) | Phenoxyacetic acid derivatives | |
| WO2001094312A3 (en) | Indolinone derivatives as protein kinase/phosphatase inhibitors | |
| MX2009003729A (es) | Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a. | |
| GEP20105074B (en) | Pyrimidinyl aryl urea derivatives being fgf inhibitors | |
| WO2008074997A8 (en) | Pyridine benzamides and pyrazine benzamides used as pkd inhibitors | |
| WO2007065664A3 (en) | Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors | |
| MX2010008719A (es) | Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina. | |
| MA32729B1 (fr) | Derives d'acide 1-amino-2-cyclobutylethylboronique | |
| MXPA05011536A (es) | Acidos carboxilicos substituidos con fenilo como inhibidores de la proteina tirosina fosfatasa-1b. | |
| WO2008137758A3 (en) | Amino acid lipids and uses thereof | |
| NO20054769D0 (no) | Substituerte fenylalkansyrer | |
| MY155836A (en) | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators | |
| EA020703B9 (ru) | Пиразолохиназолины | |
| WO2007089857A3 (en) | Substituted imidazole derivatives and their use as ptpase inhibitors | |
| BRPI0514448A (pt) | derivados do ácido bifenil-oxiacético para uso no tratamento de doenças respiratórias | |
| CY1112115T1 (el) | Παραγωγα φαινοξυοξικου οξεος χρησιμα για τη θεραπευτικη αντιμετωπιση ασθενειων του αναπνευστικου | |
| MX2010007714A (es) | Piridinas fusionadas activas como inhibidores de c-met. | |
| MX2009011878A (es) | Compuestos antagonistas de acido ribonucleico para la modulacion de beta-catenina. | |
| TW200630327A (en) | Substituted phenylalkanoic acids | |
| WO2010033978A3 (en) | IMIDAZO[1,2-α ]PYRIDINYL BISPHOSPHONATES | |
| DE602007011384D1 (de) | Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed-disäure | |
| TW200745066A (en) | Novel PTP1B inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 24 JAN 2015 BY AJ PARK Effective date: 20130621 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JAN 2016 BY CPA GLOBAL Effective date: 20141211 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JAN 2017 BY CPA GLOBAL Effective date: 20151224 |
|
| LAPS | Patent lapsed |